Explore

Trendline Trendline
Merck Ends Development of TROP ADC Amidst Strategic Pipeline Adjustments

Merck Ends Development of TROP ADC Amidst Strategic Pipeline Adjustments

Merck Ends Development of TROP ADC Amidst Strategic Pipeline Adjustments
Trendline Trendline
Novartis Unveils North Carolina API Plant as Part of $23 Billion U.S. Expansion

Novartis Unveils North Carolina API Plant as Part of $23 Billion U.S. Expansion

Novartis Unveils North Carolina API Plant as Part of $23 Billion U.S. Expansion
Trendline Trendline
Bristol Myers Squibb Positions Cobenfy as a Safer Option for Alzheimer's Psychosis

Bristol Myers Squibb Positions Cobenfy as a Safer Option for Alzheimer's Psychosis

Bristol Myers Squibb Positions Cobenfy as a Safer Option for Alzheimer's Psychosis
Trendline Trendline
Merck Discontinues TROP ADC Development Amid Strategic Shifts

Merck Discontinues TROP ADC Development Amid Strategic Shifts

Merck Discontinues TROP ADC Development Amid Strategic Shifts
Trendline Trendline
Eli Lilly's Stock Rises Following Strong Q1 Results and Raised Guidance

Eli Lilly's Stock Rises Following Strong Q1 Results and Raised Guidance

Eli Lilly's Stock Rises Following Strong Q1 Results and Raised Guidance
Trendline Trendline
Acadia Pharmaceuticals Announces Retirement of R Head Elizabeth H.Z. Thompson, Ensuring Continuity in Alzheimer's Research

Acadia Pharmaceuticals Announces Retirement of R Head Elizabeth H.Z. Thompson, Ensuring Continuity in Alzheimer's Research

Acadia Pharmaceuticals Announces Retirement of R Head Elizabeth H.Z. Thompson, Ensuring Continuity in Alzheimer's Research
Trendline Trendline
Avalyn Pharma Targets $300 Million in Upscaled IPO for Respiratory Therapies

Avalyn Pharma Targets $300 Million in Upscaled IPO for Respiratory Therapies

Avalyn Pharma Targets $300 Million in Upscaled IPO for Respiratory Therapies
Trendline Trendline
Seaport Therapeutics Prices Upsized IPO, Raising $254.9 Million

Seaport Therapeutics Prices Upsized IPO, Raising $254.9 Million

Seaport Therapeutics Prices Upsized IPO, Raising $254.9 Million
Trendline Trendline
Eli Lilly Exceeds Q1 Expectations with Strong Sales of Zepbound and Mounjaro

Eli Lilly Exceeds Q1 Expectations with Strong Sales of Zepbound and Mounjaro

Eli Lilly Exceeds Q1 Expectations with Strong Sales of Zepbound and Mounjaro
Trendline Trendline
Corcept Therapeutics Reports Q1 2026 Financial Results and FDA Approval of New Cancer Treatment

Corcept Therapeutics Reports Q1 2026 Financial Results and FDA Approval of New Cancer Treatment

Corcept Therapeutics Reports Q1 2026 Financial Results and FDA Approval of New Cancer Treatment
Trendline Trendline
Axsome Therapeutics' Auvelity Approved by FDA for Alzheimer's Agitation, Marking a Significant Advancement

Axsome Therapeutics' Auvelity Approved by FDA for Alzheimer's Agitation, Marking a Significant Advancement

Axsome Therapeutics' Auvelity Approved by FDA for Alzheimer's Agitation, Marking a Significant Advancement
Trendline Trendline
Pomerantz Law Firm Investigates Disc Medicine for Potential Securities Fraud

Pomerantz Law Firm Investigates Disc Medicine for Potential Securities Fraud

Pomerantz Law Firm Investigates Disc Medicine for Potential Securities Fraud